Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Tenax Therapeutics (Nasdaq: TENX) has announced its participation in the Guggenheim Healthcare Innovation Conference in Boston, scheduled for November 11-13, 2024. CEO Chris Giordano will present a company update and discuss the development of levosimendan in a fireside chat format on November 13, 2024, at 1:00 PM EST.
The presentation, which will be available via live webcast and archived recording, will showcase the company's progress in developing treatments for cardiovascular and pulmonary diseases with high unmet medical need. Investors can access the presentation through the company's investor relations webpage or the provided webcast link.
Tenax Therapeutics (Nasdaq: TENX) ha annunciato la sua partecipazione alla Guggenheim Healthcare Innovation Conference a Boston, programmata per l'11-13 novembre 2024. Il CEO Chris Giordano presenterà un aggiornamento sull'azienda e discuterà lo sviluppo di levosimendan in un formato di chat informale il 13 novembre 2024, alle 13:00 EST.
La presentazione, disponibile tramite webcast dal vivo e registrazione archiviata, metterà in evidenza i progressi dell'azienda nello sviluppo di trattamenti per malattie cardiovascolari e polmonari con un alto bisogno medico insoddisfatto. Gli investitori possono accedere alla presentazione tramite la pagina web delle relazioni con gli investitori della società o il link fornito per il webcast.
Tenax Therapeutics (Nasdaq: TENX) ha anunciado su participación en la Guggenheim Healthcare Innovation Conference en Boston, programada para el 11-13 de noviembre de 2024. El CEO Chris Giordano presentará una actualización de la empresa y discutirá el desarrollo de levosimendan en un formato de charla informal el 13 de noviembre de 2024, a la 1:00 PM EST.
La presentación, que estará disponible a través de un webcast en vivo y una grabación archivada, mostrará el progreso de la empresa en el desarrollo de tratamientos para enfermedades cardiovasculares y pulmonares con una alta necesidad médica no satisfecha. Los inversionistas pueden acceder a la presentación a través de la página de relaciones con inversionistas de la compañía o del enlace de webcast proporcionado.
Tenax Therapeutics (Nasdaq: TENX)는 2024년 11월 11일부터 13일까지 보스턴에서 열리는 구겐하임 의료 혁신 컨퍼런스에 참석한다고 발표했습니다. CEO인 Chris Giordano는 2024년 11월 13일 오후 1시 EST에 비공식 대화 형식으로 levosimendan 개발에 대한 회사 업데이트를 발표할 예정입니다.
이 발표는 실시간 웹캐스트와 아카이브 녹화로 제공되며, 높은 의료적 필요가 있는 심혈관 및 폐 질환 치료 개발에 있어 회사의 진행 상황을 보여줄 것입니다. 투자자들은 회사의 투자자 관계 웹페이지나 제공된 웹캐스트 링크를 통해 발표에 접근할 수 있습니다.
Tenax Therapeutics (Nasdaq: TENX) a annoncé sa participation à la Guggenheim Healthcare Innovation Conference à Boston, prévue du 11 au 13 novembre 2024. Le PDG Chris Giordano présentera une mise à jour de l'entreprise et discutera du développement de levosimendan lors d'une discussion informelle le 13 novembre 2024 à 13h00 EST.
La présentation, qui sera disponible par le biais d'un webcast en direct et d'un enregistrement archivé, mettra en avant les progrès de l'entreprise dans le développement de traitements pour les maladies cardiovasculaires et pulmonaires avec un besoin médical non satisfait élevé. Les investisseurs peuvent accéder à la présentation via la page des relations avec les investisseurs de la société ou le lien de webcast fourni.
Tenax Therapeutics (Nasdaq: TENX) hat die Teilnahme an der Guggenheim Healthcare Innovation Conference in Boston angekündigt, die für den 11.-13. November 2024 geplant ist. CEO Chris Giordano wird am 13. November 2024 um 13:00 Uhr EST im Rahmen eines informellen Gesprächs ein Unternehmensupdate präsentieren und über die Entwicklung von levosimendan sprechen.
Die Präsentation, die sowohl über einen Live-Webcast als auch eine archivierte Aufzeichnung verfügbar sein wird, wird die Fortschritte des Unternehmens bei der Entwicklung von Behandlungen für kardiovaskuläre und pulmonale Erkrankungen mit einem hohen ungedeckten medizinischen Bedarf präsentieren. Investoren können auf die Präsentation über die Investor-Relations-Webseite des Unternehmens oder den bereitgestellten Webcast-Link zugreifen.
- None.
- None.
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast.
Format: Fireside Chat
Presenter: Chris Giordano, President & Chief Executive Officer
Date and time: November 13, 2024 at 1:00 PM EST
Webcast: https://wsw.com/webcast/guggen/tenx/1967811
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize I.V., subcutaneous, and oral formulations of levosimendan. Tenax also is developing a unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax’s common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contacts
Investor Contact:
John Fraunces
Managing Director
LifeSci Advisors, LLC
C: 917-355-2395, or
Brian Mullen
LifeSci Advisors, LLC
C: 203-461-1175
FAQ
When is Tenax Therapeutics (TENX) presenting at the Guggenheim Healthcare Conference 2024?
What will be discussed at Tenax Therapeutics' (TENX) Guggenheim Conference presentation?
How can investors access Tenax Therapeutics' (TENX) Guggenheim Conference presentation?
